Trial · NCT02494778
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
NCT02494778, Phase 2, Terminated, Prilenia; results first posted 2021-09-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease. Trials, record NCT02494778. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02494778
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
- NCT number
- NCT02494778
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 248 participants, actual
- Lead sponsor
- Prilenia
- Conditions
- Huntington's Disease
- Interventions
- Pridopidine
- First posted
- 2015-07-10
- Last updated
- 2021-09-17
- Other registries' IDs
- eudract:2015-000904-24
- Results first posted
- 2021-09-17
- Limitations and caveats
This was an open-label extension of study TV7820-CNS-20002. It was terminated on 10 Nov 2017, as it was considered by the sponsor to have served its purpose in providing long-term safety data. Study termination was not based on safety concerns.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Adverse Events | 106 weeks | From signature of the informed consent form through the end of the study, which was defined as Week 106 |
| Secondary | Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Inter-Onset-interval-SD-Hand | Week 52; end of treatment (EOT) which was planned to occur at Week 104 | Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Inter-Onset-interval-SD-Hand, measured in seconds. Positive change from baseline indicates worsening. |
| Secondary | Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Peak-Force-CV-Hand | Week 52; end of treatment (EOT) which was planned to occur at Week 104 | Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Peak-Force-CV-Hand, measured in %. Positive change from baseline indicates worsening. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Adverse Events | 106 weeks | All patients enrolled who received at least one dose of study drug | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Inter-Onset-interval-SD-Hand | Week 52; end of treatment (EOT) which was planned to occur at Week 104 | All patients enrolled who received at least 1 dose of study drug and had at least 1 post-baseline UHDRS-TMS assessment. | second | MEAN |
| SECONDARY | Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Peak-Force-CV-Hand | Week 52; end of treatment (EOT) which was planned to occur at Week 104 | All patients enrolled who received at least 1 dose of study drug and had at least 1 post-baseline UHDRS-TMS assessment. | percentage | MEAN |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events | Pridopidine 45 mg BID | 193 | Participants | ||
| Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Inter-Onset-interval-SD-Hand | Pridopidine 45 mg BID | Change from baseline to Week 52 | 0.0 | Standard Deviation 0.05 | second |
| Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Inter-Onset-interval-SD-Hand | Pridopidine 45 mg BID | Change from baseline to EOT | -0.1 | Standard Deviation 0.01 | second |
| Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Peak-Force-CV-Hand | Pridopidine 45 mg BID | Change from baseline to Week 52 | -2.9 | Standard Deviation 9.31 | percentage |
| Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Peak-Force-CV-Hand | Pridopidine 45 mg BID | Change from baseline to EOT | -5.9 | Standard Deviation 8.05 | percentage |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pridopidine 45 mg BID | 248 | |
| Overall Study | COMPLETED | Pridopidine 45 mg BID | 27 | |
| Overall Study | NOT COMPLETED | Pridopidine 45 mg BID | 221 |
Source ClinicalTrials.gov
Adverse events54
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fall | Injury, poisoning and procedural complications | Pridopidine 45 mg BID | 74 | 248 | 163 |
| other | Contusion | Injury, poisoning and procedural complications | Pridopidine 45 mg BID | 13 | 248 | 20 |
| other | Weight decreased | Investigations | Pridopidine 45 mg BID | 13 | 248 | 13 |
| other | Chorea | Nervous system disorders | Pridopidine 45 mg BID | 23 | 248 | 30 |
| other | Headache | Nervous system disorders | Pridopidine 45 mg BID | 14 | 248 | 19 |
| other | Insomnia | Psychiatric disorders | Pridopidine 45 mg BID | 20 | 248 | 27 |
| other | Anxiety | Psychiatric disorders | Pridopidine 45 mg BID | 16 | 248 | 17 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Pridopidine 45 mg BID | 14 | 248 | 15 |
| other | Nasopharyngitis | Infections and infestations | Pridopidine 45 mg BID | 29 | 248 | 36 |
| serious | Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Pridopidine 45 mg BID | 1 | 248 | 1 |
1 to 10 of 54Source ClinicalTrials.gov
See all 54 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pridopidine 45 mg BID | 3 | 248 |
| Total, other adverse events | Pridopidine 45 mg BID | 191 | 248 |
| Total, serious adverse events | Pridopidine 45 mg BID | 31 | 248 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30572891 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02494778
GET https://conductscience.org/api/trials/v1/NCT02494778/events?page=2